Osteoporosis International

, Volume 29, Issue 9, pp 2159–2160 | Cite as

Bisphosphonate use after clinical fracture and risk of new fracture: response to comments by Wu et al.

  • J. Bergman
  • A. Nordström
  • P. NordströmEmail author
Letter to the Editor



This work was supported by the Swedish Research Council (2016-02584).


  1. 1.
    Wu Q-Y, Yuan F-L, Wang B, Li X (2018) Comments on Bergman et al.: Bisphosphonate use after clinical fracture and risk of new fracture. Osteoporos Int.
  2. 2.
    Bergman J, Nordstrom A, Nordstrom P (2018) Bisphosphonate use after clinical fracture and risk of new fracture. Osteoporos Int 29:937–945.
  3. 3.
    Cummings P (2003) Reporting statistical information in medical journal articles. Arch Pediatr Acolesc Med 157:321–324. CrossRefGoogle Scholar
  4. 4.
    Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396. CrossRefPubMedGoogle Scholar
  5. 5.
    Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252. CrossRefPubMedGoogle Scholar
  6. 6.
    Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102. CrossRefPubMedGoogle Scholar
  7. 7.
    MacLean C, Maglione M, McMahon M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:97–213. CrossRefGoogle Scholar
  8. 8.
    Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723. CrossRefPubMedGoogle Scholar
  9. 9.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23. CrossRefPubMedGoogle Scholar
  10. 10.
    Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789. CrossRefPubMedGoogle Scholar
  11. 11.
    Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of Community Medicine and Rehabilitation, Unit of Geriatric MedicineUmeå UniversityUmeåSweden
  2. 2.Department of Public Health and Clinical Medicine, Unit of Occupational and Environmental MedicineUmeå UniversityUmeåSweden
  3. 3.School of Sport SciencesArctic University of NorwayTromsøNorway

Personalised recommendations